NASDAQ:TCDATricida Stock Price, Forecast & News

Tricida's stock was trading at $28.05 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TCDA shares have decreased by 5.6% and is now trading at $26.49. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Tricida.

Tricida is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Tricida.

Tricida Inc (NASDAQ:TCDA) issued its earnings results on Thursday, May, 7th. The company reported ($1.49) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.41) by $0.08. View Tricida's earnings history.

2 brokers have issued 12 month price objectives for Tricida's shares. Their forecasts range from $50.00 to $50.00. On average, they expect Tricida's share price to reach $50.00 in the next twelve months. This suggests a possible upside of 88.8% from the stock's current price. View analysts' price targets for Tricida.

Media stories about TCDA stock have trended negative on Sunday, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Tricida earned a news sentiment score of -2.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the company's share price in the next few days. View the latest news about Tricida.

Tricida saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 4,740,000 shares, an increase of 5.3% from the June 15th total of 4,500,000 shares. Based on an average trading volume of 334,200 shares, the days-to-cover ratio is presently 14.2 days. Approximately 12.3% of the company's stock are short sold. View Tricida's Current Options Chain.

Some companies that are related to Tricida include Reata Pharmaceuticals (RETA), Ultragenyx Pharmaceutical (RARE), Mirati Therapeutics (MRTX), Zai Lab (ZLAB), Arrowhead Pharmaceuticals (ARWR), Emergent Biosolutions (EBS), Myokardia (MYOK), Blueprint Medicines (BPMC), Nektar Therapeutics (NKTR), Biohaven Pharmaceutical (BHVN), Global Blood Therapeutics (GBT), Evotec (EVTCY), Amicus Therapeutics (FOLD), GW Pharmaceuticals PLC- (GWPH) and FibroGen (FGEN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Gilead Sciences (GILD), Madrigal Pharmaceuticals (MDGL), Myovant Sciences (MYOV), Arena Pharmaceuticals (ARNA), Atara Biotherapeutics (ATRA), Biohaven Pharmaceutical (BHVN), Crispr Therapeutics (CRSP), CytomX Therapeutics (CTMX), Exelixis (EXEL) and Amicus Therapeutics (FOLD).

(TCDA) raised $175 million in an initial public offering on Thursday, June 28th 2018. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen acted as the underwriters for the IPO.

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TCDA stock can currently be purchased for approximately $26.49.

Tricida has a market capitalization of $1.32 billion. The company earns $-176,810,000.00 in net income (profit) each year or ($3.72) on an earnings per share basis. Tricida employs 76 workers across the globe.

The official website for Tricida is www.tricida.com.

Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-429-7800 or via email at [email protected]